This whitepaper details how IRBM integrates digital pathology, spatial multi-omics (transcriptomics, proteomics, and metabolomics), and AI-driven machine learning to map cellular microenvironments and tissue architecture. By analyzing these complex spatial relationships, the framework aims to accelerate drug discovery, uncover therapeutic targets, and identify novel biomarkers across oncology and neurodegeneration.
Sponsored by
IRBM
IRBM is a leading drug discovery organization with a proven track record of bringing three therapeutics to market across oncology, neurology, infectious, and rare diseases. Independent since 2010, the company partners with global biotech, pharma, and research institutions to deliver both standalone specialized services and fully integrated, efficient drug discovery programs.